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Abstract
The proto-oncogene Bcl6 and its family gene, BAZF, encode a sequence-specific transcriptional repressor which contains
the BTB/POZ domain in NH2-terminal region and zinc finger motifs in COOH-terminal region. The BTB/POZ domain and
the middle portion of Bcl6 and BAZF are known to display transrepressor activity. Since we have identified the identical 17-
amino acid (aa) sequence in the middle portion of Bcl6 and BAZF, the 17aa region may be another repressive domain of the
middle portion. The reporter gene assay indicates that the 27aa sequence including the 17aa region recruits histone
deacetylases to express transrepressor activity. Furthermore, overexpression of Bcl6 or Bcl6(POZ3) (Bcl6 deleted with the
BTB/POZ domain) induced apoptosis in NIH3T3 cells, and the apoptosis was inhibited by the addition of histone
deacetylase inhibitor in the culture. However, apoptosis was not induced in NIH3T3 cells by overexpression of Bcl6(POZ3)
deleted with the 17aa region. These results indicate that the 17aa region in the middle portion of Bcl6 is a functional domain
of transrepressor activity and is responsible for inducibility of apoptosis in NIH3T3 cells. ß 2001 Elsevier Science B.V. All
rights reserved.
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1. Introduction
Chromosomal translocations involving 3q27 have
been detected in some non-Hodgkin’s lymphomas,
particularly in di¡use large B-cell lymphomas [1,2].
The human proto-oncogene Bcl6 has been identi¢ed
from the chromosomal breakpoints [3^5]. The Bcl6
gene encodes a 706-amino acid (aa) nuclear protein
which contains a BTB/POZ domain in NH2-terminal
region and six Kru«ppel-like zinc ¢nger motifs in
COOH-terminal region, and Bcl6 acts as a se-
quence-speci¢c transcriptional repressor [6,7]. Two
noncontiguous regions of Bcl6 (the BTB/POZ do-
main and the middle portion) express transrepressor
activity. We have recently isolated BAZF, a family
member of Bcl6, that is also composed of a BTB/
POZ domain and zinc ¢nger motifs, and acts as a
sequence-speci¢c transcriptional repressor [8]. Since
the 17aa sequence (aa 188 to aa 204) in the middle
portion of BAZF is 100% identical to that (aa 370 to
aa 386) in the middle portion of Bcl6, the 17aa re-
gion may be another repressive domain of Bcl6 and
BAZF. Since the BTB/POZ domain of Bcl6 interacts
with silencing mediator of retinoid and thyroid re-
ceptor protein (SMRT) [9^12] and SMRT forms a
repressive complex with histone deacetylase 1
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(HDAC 1) [13,14], Bcl6 may repress transcription of
target genes by locally inducing a repressive (hypo-
acetylated) chromatin structure through mechanisms
involving SMRT recruitment and histone deacetyla-
tion. However, molecular mechanisms of transrepres-
sion by the middle portion of Bcl6 are not known.
Expression of Bcl6 is ubiquitous [15] and is pref-
erential in germinal center B cells [16,17]. The germi-
nal center formation is defective in Bcl6-de¢cient
(Bcl63=3) mice [18^20]. Since Bcl63=3 mice display
massive myocarditis at an adult age, Bcl6 in cardiac
myocytes may play a role in protecting cell death of
myocytes [21]. Furthermore, in vitro gene transfec-
tion experiments demonstrated that overexpression
of Bcl6 enhances the viability of di¡erentiating myo-
cytes by preventing them from apoptosis [22]. How-
ever, the overexpression induces apoptosis in CV-1
and HeLa cells [23]. Therefore, the role of Bcl6 in
protection of apoptosis has remained controversial.
Apoptosis is an intrinsic cell suicide program that is
universal in metazoan organism [24]. Cells under-
going apoptosis display a series of morphological
characteristics including cytoplasm shrinkage, chro-
matin condensation, membrane blebbing, DNA frag-
mentation and generation of apoptotic bodies [25].
Apoptosis is an active gene-directed process, and a
number of proteins including transcription factors
[26^30] can trigger apoptotic cell death. Moreover,
apoptosis can be elicited by overexpression of tran-
scriptional repressors [31,32]. Here we show that the
17aa region in the middle portion of Bcl6 and BAZF
expressed transrepressor activity in vitro by recruit-
ing HDACs on target genes. Furthermore, overex-
pression of Bcl6 or Bcl6(POZ3) (Bcl6 deleted with
the BTB/POZ domain) induced apoptosis in NIH3T3
cells and the 17aa region of Bcl6(POZ3) was critical
for the induction of apoptosis.
2. Materials and methods
2.1. Assay for transcriptional repressor activity with
the luciferase reporter gene
Luciferase reporter plasmids and some of the Gal4
fusion genes have been described previously [8].
Gal4-BAZF(Mid27aa) was constructed as follows:
the Mid27aa (532^612) fragment was obtained by
polymerase chain reaction (PCR) using pairs of
primers speci¢c for BAZF sequence linked to an
EcoRI site (underlined). Primer sequences: 5P-TTT-
GAATTCATGGGTTCCACAGCGGCCCCA-3P,
5P-TTTGAATTCACACGCCTGGACTACGTGTT-
3P. The PCR products were subcloned in pGEM-T
vector (Promega). An EcoRI fragment of the PCR
products was subcloned into the EcoRI site of
pSG424 carrying the Gal4(1^147) coding sequence
[33]. Translation termination was provided by
three-frame termination codons in pSG424. PCR-de-
rived products as well as subcloning junctions were
veri¢ed by sequence analysis. Gal4-Bcl6(Mid) was
constructed as follows: the fragment of Bcl6(Mid)
(566^1561) was obtained by PCR with following
primers: 5P-AAAGGATCCATGCCACTGAGAAA-
TACTCCC-3P with a BamHI site and an ATG start
codon (underlined) and 5P-TTTGAATTCGAA-
GAAGGTCCCATTCTCA-3P with a new EcoRI
site (underlined). An EcoRI fragment of the PCR
products was subcloned into the EcoRI site of
pSG424 carrying the Gal4(1^147) coding sequence.
Translation termination was provided by three-frame
termination codons in pSG424. For construction of
Gal4-Bcl6(Mid)(17aa3), a fragment without the
BTB/POZ domain of Bcl6 (499^1082) was obtained
by PCR with following primers: 5P-AAAGGATC-
CATGCCACTGAGAAATACTCCC-3P with a new
BamHI site and a start codon (underlined) and 5P-
AGTCTAGAAAGGATGCAGGCGTTCTTGCT-3-
P) with a new XbaI site (underlined). The Bcl6 frag-
ment (1162^1561) was made by PCR. The sequence
(5P-AATCTAGAAGCCTCAATCAGAATGCC-3P)
with a new XbaI site (underlined) was synthesized as
a primer. A XbaI^SpeI fragment was subcloned into
the XbaI site of the fragment of Bcl6 without BTB/
POZ domain (499^1082) in pGEM-T Easy vector,
then the EcoRI fragment of Bcl6(Mid)(17aa3) was
subcloned into the EcoRI site of pSG424. PCR-de-
rived products as well as subcloning junctions were
veri¢ed by sequence analysis.
NIH3T3 cells were cultured in Dulbecco’s modi-
¢ed Eagle’s medium (DMEM, Life Technologies)
plus 10% fetal calf serum (FCS; Sigma) containing
penicillin G (100 U/ml) and streptomycin (100 Wg/
ml). NIH3T3 cells were plated at 3.3U105 cells per
60-mm-diameter dish 1 day before transfection. Var-
ious expression plasmids, p5GBS luc (luciferase re-
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porter plasmid) (0.5 Wg), and pRL-tk (0.05 Wg)
(Promega) or pRL-SV40 (0.5 Wg) (Promega) as a
transfection e⁄ciency control in 6 Wl of Lipofectam-
ine (Gibco BRL) in 2 ml of Opti-MEN (Gibco BRL)
were cotransfected into NIH3T3 cells for 8 h. Trans-
fected cells were cultured with DMEM with 10%
FCS for 24 h, and then further cultured with Tri-
chostatin A (TSA) (150 nM; Biomol) for 24 h. Lu-
ciferase activity in cell lysates was determined by
standard methods with Pikkagene Dual (ToyoInk).
2.2. Construction of Bcl6 expression vectors
Bcl6 expression plasmids were constructed as fol-
lows. pcDNA3-Bcl6: a BamHI fragment of Bcl6 was
inserted into pcDNA3 (Invitrogen). pcDNA3-
Bcl6(POZ3) (Bcl6 without the BTB/POZ domain):
a 670 base pairs (bp) fragment of pcDNA3-Bcl6
(566^1217) was obtained by PCR with following
primers: 5P-AAAGGATCCATGCCACTGAGAAA-
TACTCCC-3P with a BamHI site and an ATG start
codon (underlined) and 5P-AAAAGGGTAGGCTC-
GAGGGGAGAGGCGACC-3P with a XhoI site
(underlined). An EcoRI^XhoI fragment of PCR
products in pGEM-T vector was subcloned into the
EcoRI^XhoI site of pcDNA3-Bcl6 to replace the
BTB/POZ domain. pcDNA3-POZ: a fragment con-
taining the BTB/POZ domain of Bcl6 (1^520) cDNA
was obtained by PCR with following primers linked
to an EcoRI site (underlined): 5P-TTTGAATT-
CATGGCCTCCCCGGCTGACA-3P and 5P-TTT-
GAATTCGAAGAAGGTCCCATTCTCA-3P. An
EcoRI fragment of PCR products in pGEM-T vector
was subcloned into the EcoRI site of pcDNA3.
pcDNA3-Bcl6(POZ3,17aa3) (Bcl6 deleted with the
BTB/POZ domain and the 17aa sequence): a frag-
ment without the BTB/POZ domain of Bcl6 (499^
1082) was obtained by PCR with following primers:
5P-AAAGGATCCATGCCACTGAGAAATACTC-
CC-3P with a new BamHI site and a start codon
(underlined) and 5P-AGTCTAGAAAGGATGCAG-
GCGTTCTTGCT-3P) with a new XbaI site (under-
lined). PCR products were subcloned into pGEM-T
vector. A BamHI^EcoRI fragment of pcDNA3-Bcl6
(POZ3) replaced the BamHI^EcoRI fragment of
pcDNA3-Bcl6. The Bcl6 fragment (1162^1784) was
made by PCR. The sequence (5P-AATCTAGA-
AGCCTCAATCAGAATGCC-3P) with a new XbaI
site (underlined) was synthesized as a primer. A
XbaI^EcoRI fragment of PCR products was sub-
cloned into the XbaI^EcoRI site of pcDNA3-
Bcl6(POZ3) to make pcDNA3-Bcl6(POZ3,17aa3).
MSCV/Bcl6-IRES-EGFP: pcDNA3-Bcl6 was di-
gested with BamHI and SphI, then this Bcl6 frag-
ment was cloned into the BamHI^SphI site of
pREV-TRE vector (Clonech). The resulting pREV-
TRE-Bcl6 was digested with BamHI and HpaI, and
the BamHI site of this fragment was blunted. The
2166 bp BamHI (blunted)^HpaI fragment was then
cloned into the HpaI site of MSCV/IRES-EGFP
(gifts from Dr. A. Kume, Jichi Medical School, To-
chigi, Japan) [34]. pcDNA3-Bcl6-ER: the EcoRI^
BglII fragment without stop codon (about 330 bp)
in Bcl6 cDNA was obtained by PCR. PCR products
were inserted in pGEM-T vector (pGEM-Bcl6).
pMV-7-myc-ER (gifts from Dr. E. Bossy-Wetzel, In-
stitute Pasteur, France) [26] was digested with Bam-
HI. The resulting 954 bp fragment, containing a part
of the human estrogen receptor (ER) gene, was
cloned into the BglII site of pGEM-Bcl6. The result-
ing Bcl6-ER gene was digested with EcoRI and the
1284 bp fragment was subcloned into the EcoRI site
of pcDNA3. pcDNA3-Bcl6(POZ3)-ER: the EcoRI^
XhoI fragment of pcDNA3-Bcl6(POZ3) was sub-
cloned into the EcoRI^XhoI site of pcDNA3-Bcl6-
ER to replace the BTB/POZ domain. All PCR-de-
rived products as well as subcloning junctions were
veri¢ed by DNA sequence.
2.3. Immunoblot analysis
NIH3T3 cells were transiently transfected with
pcDNA3-Bcl6, pcDNA3-Bcl6(POZ3), pcDNA3-
Bcl6(POZ3,17aa3) or pcDNA3 control vector.
Bcl6 protein in transfectants was detected by immu-
noblot analysis [21]. Brie£y, cells were lysed in IP
bu¡er 24 h after transfection. Aliquots of cell lysate
were reacted with 2 Wg of anti-Bcl6 antibody (C-19:
sc-368, Toyobo) for 1 h at 4‡C. Immune complexes
were precipitated with protein G-Sepharose beads
(Zymed) for 2 h at 4‡C. Immunoprecipitates were
washed three times with IP bu¡er, analyzed by so-
dium dodecyl sulfate^polyacrylamide gel electropho-
resis and transferred to a polyvinyl di£uoride mem-
brane (Immobilon-P, Millipore). Blots were
incubated with rabbit anti-Bcl6 antibody [20] fol-
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lowed by horseradish peroxidase conjugated donkey
anti-rabbit immunoglobulin (Amersham) for 1 h at
each step, and developed with enhanced chemilumi-
nescence reagents (Amersham International).
2.4. Generation of Bcl-xL transfected cell lines
The XbaI fragment of rat Bcl-xL cDNA was sub-
cloned into an XbaI site of the plasmid pEF-BOS,
which harbors an elongation factor 1K promoter
(gifts from Dr. S. Ohta, Nippon Medical School,
Kawasaki, Japan) [35]. pEF-BOS/Bcl-xL (20 Wg)
was transfected into NIH3T3 with 1 Wg of pST-
neoB, which carries a neomycin-resistant gene [36].
Transfection was performed by electroporation with
a Gene Pulser (Bio-Rad) at 0.23 kV in a 0.4-cm cell.
After selection with 0.5 mg/ml geneticin G418 (Life
Technologies), two clones that stably expressed the
exogenous Bcl-xL gene were established. Clone 26^11
and 26^9 expressed the highest and the lowest level
of Bcl-xL mRNA among transfectants, respectively
(data not shown). Parental NIH3T3 cells as well as
two NIH3T3 clones transfected with pST-neoB (neo-
1 and neo-2) were used as controls. Cell morphology,
proliferative behavior and expression of Bcl-2 and
Bax mRNA were comparable between Bcl-xL trans-
fectants and parental NIH3T3 (data not show).
2.5. Transient transfection assay and X-gal staining
NIH3T3 cells were seeded at a density of 1U106
cells per 6 cm dish in DMEM. Total 2 Wg of
pcDNA3 and pcDNA3-Bcl6 were co-transfected
with 0.2 Wg of a L-galactosidase expression vector
(RSV-L-gal) using Lipofectamine. Cells were rinsed
twice with PBS 12 h after transfection, and further
cultured with DMEM containing 10% FCS for 12 h.
To identify L-gal activity, cells were ¢xed with 1%
glutaraldehyde in PBS for 5 min at room tempera-
ture, washed twice with PBS and stained with X-gal
solution (0.5 mg/ml 5-chromo-4-chloro-3-indoxyl
L-gal, 3 mM K3Fe(CN)6, 3 mM K4Fe(CN)6. 3H2O,
1 mM MgCl2, 10 mM KCl, 0.1% Triton X-100 in
PBS). For transient transfection death assay [37],
NIH3T3 cells were seeded at a density of 3U105 cells
per 6 cm dish in DMEM without phenol red and
10% activated-charcoal-treated FCS. Total 0.5 Wg
of pcDNA3 and pcDNA3-Bcl6-ER or pcDNA3-
Bcl6 were cotransfected with 1.5 Wg of RSV-L-gal
using Lipofectamine. Cells were rinsed twice with
PBS 12 h after transfection, and further cultured
with DMEM containing 10% FCS for 20 h. Cells
were lysed in 500 Wl of lysis bu¡er containing 25
mM Tris^HCl (pH 7.8), 2 mM dithiothreitol, 10%
glycerol, 1 mM EDTA, and 1% Triton X-100. Sam-
ples (20 Wl) were then analyzed for L-gal activity as
described. Percent cytotoxicity is calculated with the
formula: Percent cytotoxicity = 1003(experimental
L-gal/medium control L-gal)U100.
2.6. Flow cytometric analysis
Cell DNA analysis was performed as described by
Lamm et al. [38]. Brie£y, NIH3T3 cells were trans-
fected with Bcl6-EGFP (15 Wg) or EGFP (15 Wg)
using Lipofectamine. Then, cells were cultured with
DMEM with 10% FCS for 16 h. Cells were resus-
pended in 300 Wl of PBS and added 5 ml of ice-cold
75% ethanol drop-wise under agitation. Cell pellets
were washed twice with PBS and then resuspended in
PBS containing 50 Wg/ml propidium iodide and 50
Wg/ml DNase-free RNase A (Roche Molecular Bio-
chemicals). Cells were incubated for 1 h on ice and
then analyzed DNA content on a FACSCalibur
(Becton Dickinson) using Cell Quest software (Bec-
ton Dickinson) for Macintosh (Apple Computer).
3. Results
3.1. The 17aa region in the middle portion of Bcl6 and
BAZF expresses transrepressor activity by
recruiting HDACs
To examine repressor activity of the 17aa region of
Bcl6 and BAZF, the Gal4-fusion gene of Bcl6 or
BAZF and p5GBS luc that carries the luciferase re-
porter gene with Gal4-binding DNA sequence were
cotransfected into NIH3T3 cells. Fig. 1 shows that
repressor activity of Gal4-Bcl6 (Fig. 1A) and Gal4-
BAZF (Fig. 1B) associated with the BTB/POZ do-
mains and the middle portion. However, the Gal4-
Bcl6(Mid)(17aa3) and Gal4-BAZF(Mid)(17aa3)
genes that encode the middle portion lacking the
17aa region lost repressor activity. Furthermore,
Gal4-BAZF(Mid27aa) that encodes 27aa including
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the 17aa region expressed the activity, indicating that
the 17aa region is likely to be a novel activity domain
of transcriptional repressors.
Since the corepressor SMRT binds to the BTB/
POZ domain of Bcl6 [9], the repressor activity of
Bcl6 may be explained by remodeling of the chroma-
tin structure by recruiting a complex of SMRT, mSI-
N3A and HDAC1 [13,14]. To address the functional
relevance of the ability of the 17aa region in the
middle portion of Bcl6 and BAZF to recruit a
Fig. 1. The 17aa region of Bcl6 and BAZF displays transcriptional repressor activity. Schematic representation of Gal4-Bcl6 (A) and
Gal4-BAZF (B) fusion proteins and their repressor activity. Various Gal4-fusion genes (0.5 Wg) were cotransfected with p5GBS luc
(0.5 Wg) into NIH3T3 cells. pRL-tk was also cotransfected in each experiment to serve as an internal control for transfection e⁄-
ciency. Cells were cultured with (closed bar) or without (dotted bar) TSA (150 nM). Luciferase activity in lysates was measured 48 h
after transfection. The activity was expressed as a percentage of luciferase activity in NIH3T3 cells transfected with Gal4 and p5GBS
luc. The data presented are representative of three independent experiments, and error bars are shown. In the schematic representa-
tion, hatched and stippled boxes indicate the BTB/POZ domain and the 27aa region including the conserved 17aa sequence in the
middle portion, respectively.
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Fig. 2. Overexpression of Bcl6 induces apoptosis in NIH3T3 cells. NIH3T3 cells were transiently transfected with pcDNA3-Bcl6 or
pcDNA3 together with a plasmid expressing the L-gal gene. (A) cells were ¢xed 24 h after transfection and incubated with X-gal solu-
tion to visualize L-gal-positive cells. (B) transient transfection death assay. NIH3T3 cells were transfected with pcDNA3-Bcl6 and
pcDNA3 (total 0.5 Wg) together with a plasmid expressing the L-gal gene. Cells were harvested and assayed for L-gal activity 24 h
after transfection. Percent cytotoxicity is shown for each group. Results represent the means and variations (S.E.M.) of three wells.
(C) £ow cytometric analysis of Bcl6-transfected NIH3T3 cells. NIH3T3 cells were transfected with Bcl6-EGFP. Cells were ¢xed 24 h
after transfection and the nuclei were stained with propidium iodide. DNA contents in the nuclei of GFP positive cells were deter-
mined by FACS. Percentage of nuclei in apoptosis phase (the ¢rst peak) was indicated. The data presented are representative of two
independent experiments.
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HDAC complex, we examined whether the addition
of an inhibitor of HDACs in the culture could block
Gal4-BAZF(Mid27aa)-mediated transcriptional re-
pression or not. TSA is a potent and speci¢c inhib-
itor of HDAC activity and is active in nanomolar
concentration [39]. The addition of TSA (150 nM)
inhibited Bcl6- and BAZF-mediated transcriptional
repression. Furthermore, the BTB/POZ-mediated
and the BAZF(Mid27aa)-mediated transcriptional
repression also decreased by the addition of TSA.
These results suggest that the 17aa region in the mid-
dle portion of Bcl6 and BAZF can recruit HDACs to
express transrepressor activity.
3.2. Overexpression of Bcl6 in NIH3T3 cells induces
apoptosis
When the Bcl6 gene was transfected into NIH3T3
cells, we could not make any stable transfectants,
suggesting induction of cell death by Bcl6 overex-
pression. To examine the inducibility of cell death,
pcDNA3-Bcl6 and RSV-L-gal were transiently co-
transfected into NIH3T3 cells. When L-gal activity
in transfectants was histochemically detected by
X-gal staining, many of the blue stained cells exhib-
ited shrunken cell shape, condensed chromatin and
cytoplasmic blebs (Fig. 2A), suggesting cell death by
apoptosis. By contrast, transfection with pcDNA3
and RSV-L-gal revealed mainly normal and healthy
looking blue stained cells. Furthermore, we con-
¢rmed the induction of cell death in NIH3T3 cells
by the transient transfection death assay. Various
amounts of expression vectors (pcDNA3 and
pcDNA3-Bcl6) were cotransfected with a L-gal ex-
pression vector into NIH3T3 cells. The cells were
harvested 24 h after transfection, and L-gal activity
in survived cells was analyzed. Cytotoxicic activity
was related with the amount of Bcl6 transfected
(Fig. 2B). We next con¢rmed that a type of the cell
death was apoptosis by measuring the amount of
DNA content in dying cells [38,40]. NIH3T3 cells
were transfected with MSCV-Bcl6/IRES-EGFP, and
DNA in those cells was stained with propidium
iodide 24 h after transfection. Apoptosis of transi-
ently transfected cells was detected by £ow cytometry
(Fig. 2C). Percentage of apoptotic (subdiploid) cells
in MSCV-Bcl6/IRES-EGFP transfectants was sub-
stantially larger than that in control although cell
cycle patterns from G1 to G2/M phase was similar
between them. These results indicate that overexpres-
sion of Bcl6 induces apoptosis in NIH3T3 cells.
Transrepressor activity of Bcl6 has been mapped
Fig. 3. Overexpression of the BTB/POZ domain or the middle portion of Bcl6 induces apoptosis in NIH3T3 cells. NIH3T3 cells were
transiently transfected with pcDNA3-Bcl6 (open square), pcDNA3-Bcl6(POZ3) (closed square), pcDNA3-POZ (open circle) or
pcDNA3 (open triangle) together with a plasmid expressing the L-gal gene. Percentage of cytotoxicity of NIH3T3 cells was measured
by the transient transfection death assay. (A) NIH3T3 cells were harvested 24 h after transfection. (B) NIH3T3 cells were harvested
various times after transfection. Results represent the means and variations (S.E.M.) of three wells.
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to the BTB/POZ domain and the 17aa region in the
middle portion. To analyze which regions of Bcl6 are
related with induction of apoptosis, inducibility of
apoptosis in NIH3T3 cells with overexpression of
several Bcl6 mutant constructs was analyzed by the
transient transfection death assay. Fig. 3 shows that
apoptosis was induced in NIH3T3 cells transfected
with either pcDNA3-POZ or pcDNA3-Bcl6(POZ3).
POZ-mediated apoptosis reached to the plateau level
of cytotoxicity (within 12 h) 12 h earlier than
Bcl6(POZ3)-mediated cell death did (within 24 h).
Furthermore, the plateau level (70%) of POZ-medi-
ated cytotoxicity was lower than that (90%) of
Bcl6(POZ3)-mediated apoptosis (Fig. 3B).
Overexpression of Bcl-xL inhibits apoptosis in
many experimental systems [41,42]. E¡ect of Bcl-xL
overexpression on the POZ-mediated and the
Bcl6(POZ3)-mediated apoptosis was analyzed by
the transient transfection death assay. Bcl-xL trans-
fectants and control cells were transiently transfected
with pcDNA3-POZ or pcDNA3-Bcl6(POZ3). As
presented in Fig. 4, high (s 70%) cytotoxicity
was induced in control NIH3T3 cells transfected
with pcDNA3-Bcl6, pcDNA3-POZ or pcDNA3-
Bcl6(POZ3). Overexpression of Bcl-xL could not res-
cue cell death induced by overexpression of Bcl6 or
Bcl6(POZ3). In contrast, cytotoxicity mediated by
overexpression of the BTB/POZ domain (pcDNA3-
POZ) decreased to 40% in Bcl-xL transfectants.
3.3. Overexpression of Bcl6(POZ3) induces
apoptosis by recruiting HDACs
To elucidate the molecular mechanism of
Bcl6(POZ3)-mediated apoptosis, NIH3T3 cells
were transfected with pcDNA3-Bcl6(POZ3)-ER
that encodes Bcl6(POZ3) and ER fusion protein.
Since ER was fused to the zinc ¢nger domain in
the 3P side of Bcl6(POZ3), ER may inhibit
Bcl6(POZ3) from moving into the nucleus as previ-
ously reported [43]. Those transfected cells were cul-
tured in the presence or absence of L-estradiol, and
the cell death was determined by the transient trans-
fection death assay. When Bcl6(POZ3)-ER transfec-
tants were cultured without L-estradiol, cytotoxicity
was not detected (6 10%) (Fig. 5). By contrast, the
addition of L-estradiol in the cultures of
Bcl6(POZ3)-ER transfectants induced cytotoxicity
to 43%. These data suggest that localization of
Bcl6(POZ3) in the nucleus is important to induce
apoptosis.
Since the 17aa region in the middle portion of
Bcl6(POZ3) was critical for expressing repressor ac-
Fig. 5. Apoptosis was induced in NIH3T3 cells by activation of
Bcl6-ER with estrogen. NIH3T3 cells were transfected with
pcDNA3-Bcl6(POZ3)-ER. Transfectants were seeded with 10%
FCS in the presence (closed bar) or absence (open bar) of L-es-
tradiol (2 mM) for 20 h. Percentage of cytotoxicity of NIH3T3
cells was measured by transient transfection death assay. Re-
sults represent the means and variations (S.E.M.) of three wells.
Fig. 4. E¡ect of Bcl-xL on apoptosis induced by overexpression
of Bcl6. Bcl-xL stable transfectant cells (closed bar) or control
cells (open bar) were transfected with pcDNA3-POZ or
pcDNA3-Bcl6(POZ3) together with a plasmid expressing the
L-gal gene. Percentage of cytotoxicity of NIH3T3 cells was
measured 24 h after transfection by transient transfection death
assay. Results represent the means and variations (S.E.M.) of
three wells. Paired comparisons were performed for statistical
signi¢cance by Student’s t-test. *P6 0.01.
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tivity, we examined a role of the 17aa region in the
induction of apoptosis by the transient transfection
death assay using pcDNA3-Bcl6(POZ3,17aa3) en-
coding Bcl6(POZ3) lacking the 17aa region. Those
gene products were detected in transfectants by im-
munoblot analysis (Fig. 6A). Cytotoxicity by
Bcl6(POZ3,17aa3) overexpression was signi¢cantly
lower than that by overexpression of Bcl6(POZ3)
(Fig. 6B). Furthermore, we tried to block
Bcl6(POZ3)-mediated apoptosis by the addition of
TSA in the culture (Fig. 6C). More than 50 nM of
TSA largely inhibited cell death mediated by over-
Fig. 6. The 17aa region of Bcl6 is required for induction of apoptosis in NIH3T3 cells. NIH3T3 cells were transiently transfected with
pcDNA3-Bcl6 (B: open square; C: open bar), pcDNA3-Bcl6(POZ3) (B: closed square; C: hatched bar), pcDNA3-Bcl6(PO-
Z3,17aa3) (B: closed diamond; C: closed bar), or pcDNA3 (B: open triangle) together with a plasmid expressing the L-gal gene. Ex-
pression of those genes was examined by immunoblot analysis (A). Cells were further cultured without (B) or with (C) various
amounts of TSA for 24 h. Percentage of cytotoxicity of NIH3T3 cells was measured 36 h after transfection by transient transfection
death assay. Results represent the means and variations (S.E.M.) of three wells.
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expression of Bcl6(POZ3). However, these doses of
TSA did not a¡ect viability of cells transfected with
pcDNA3-Bcl6(POZ3,17aa3).
4. Discussion
The 17aa sequence (aa 370 to aa 386) of Bcl6 is
100% identical to that (aa 188 to aa 204) of BAZF
[8]. We have mapped the repressor domain of Bcl6
and BAZF to a minimal 27aa sequence including the
17aa region that is su⁄cient to repress transcription
of the luciferase reporter gene with Gal4-binding
DNA sequence when Bcl6 and BAZF were fused to
a Gal4 DNA-binding domain. The 17aa sequence
has no homology to the known activity site of tran-
scriptional factors, and may perhaps be a novel ac-
tivity domain of transcriptional repressors. Since the
17aa-mediated transcriptional repression can be
overcome by the addition of TSA in the culture,
the 17aa region may have the ability to repress tran-
scription by recruiting HDACs. One possibility of
the mechanism to recruit HDACs by the 17aa region
of Bcl6 is a binding of the 17aa region to HDACs, as
illustrated by the cases of both Rb [44^46] and YY-1
[47]. As HDACs can make a complex with SMRT
and mSIN3A [13,14], the other possibility is that the
17aa region of Bcl6 may associate with some part of
a SMRT/mSIN3A/HDAC complex. Recent results
showed that the middle portion (aa 191 to aa 383)
of Bcl6 is able to associate with mSIN3A [12]. How-
ever, a further N-terminally truncated Bcl6 derivative
(aa 265 to aa 383) lost its ability to interact with
mSIN3A. So the 17aa sequence (aa 370 to aa 386)
in the middle portion of Bcl6 may associate with a
part of SMRT/mSIN3A/HDAC complex except
mSIN3A. The BTB/POZ domain of Bcl6 interacts
with SMRT [9^12]. Thus, the BTB/POZ domain,
the front half (aa 191 to aa 264) and the 17aa region
(aa 370 to aa 386) in the middle portion of Bcl6 may
bind to di¡erent part of the SMRT/mSIN3A/HDAC
complex to recruit it to target genes.
Overexpression of Bcl6(POZ3) in ¢broblasts was
evaluated using the transient transfection death assay
and induced apoptosis. Since overexpression of
Bcl6(POZ3,17aa3) could not induce apoptosis, the
17aa region is critical for induction of apoptosis. The
addition of TSA in the culture inhibited
Bcl6(POZ3)-mediated apoptotic cell death. Thus,
overexpression of Bcl6(POZ3) may recruit a
SMRT/mSIN3A/HDAC complex to induce apopto-
sis. When we used Bcl6(POZ3)-ER fusion protein,
apoptosis was enhanced by the addition of L-estra-
diol in the culture, suggesting that nuclear localiza-
tion of Bcl6(POZ3) is important for induction of
apoptosis. Thus, overexpression of Bcl6(POZ3)
may recruit a SMRT/mSIN3A/HDAC complex to
target genes to repress their expression and induce
apoptosis. This mechanism appears to be shared by
other POZ/zinc ¢nger-type transcriptional repressors
[48^53]. Although the previous report [23] suggest
that the cooperative down-regulation of Bcl-xL and
up-regulation of Bax may explain the mechanism of
Bcl6-mediated apoptosis in CV-1 cells, overexpres-
sion of Bcl-xL cannot rescue Bcl6(POZ3)-mediated
cell death in NIH3T3 cells, suggesting that Bcl-xL is
not a target gene.
Another interpretation of the mechanism is that
overexpression of Bcl6(POZ3) modulates HDAC
function in NIH3T3 cells by forming a SMRT/mSI-
N3A/HDAC complex. This interpretation may ex-
plain the mechanism of cell death induced by over-
expression of the BTB/POZ domain since the BTB/
POZ domain of Bcl6 does not contain the DNA-
binding zinc-¢nger motifs. The BTB/POZ domain is
an evolutionary conserved domain often found in
developmentally regulated transcription factors. The
BTB/POZ domain of Bcl6 and BAZF has homology
to NH2-terminal regions of some zinc ¢nger-type
DNA-binding proteins, such as the Drosophila tram-
track and human KUP protein. This shared domain
is important for speci¢c protein-protein interactions.
Repressor activity of Bcl6 associates with the BTB/
POZ domain like as other POZ/zinc ¢nger-type
DNA-binding proteins including ZF5 and PLZF.
The BTB/POZ domain of PLZF has been shown to
interact with SMRT [47], mSIN3A and HDAC 1
[50], indicating that PLZF is also able to recruit a
SMRT/mSIN3A/HDAC complex to target genes to
repress their expression. The crystal structure of the
BTB/POZ domain of PLZF reveals that the BTB/
POZ domain is a tightly interwound dimmer which
may be important for POZ^POZ interactions, as well
as surface features in the dimmer which may be in-
volved in interactions with other proteins [51]. The
BTB/POZ domain of Bcl6 also has the capability to
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self-interact [11] and to hetero-interact with the BTB/
POZ domain of BAZF [8]. These results suggest that
POZ-mediated cell death may be due to modulate
HDAC function in NIH3T3 cells by making a large
complex including a SMRT/mSIN3A/HDAC com-
plex by the POZ-mediated protein/protein interac-
tions.
Pathological phenotypes of Bcl63=3 mice suggest
that Bcl6 plays a role in protection of cardiac myo-
cytes [21] and spermatocytes [54] from cell death, and
germinal center B cells require a large amount of
Bcl6 for their survival [19]. Furthermore, overexpres-
sion of Bcl6 enhanced viability of di¡erentiating
myocytes by preventing apoptosis [22]. However,
the overexpression induced apoptosis in CV-1,
HeLa [23], DIF9 (pro-B cell line), mouse L (data
not shown) and NIH3T3 cells, suggesting that
function of Bcl6 is various among cell types and
di¡erentiation stages. The mechanism of apoptosis
induced by the overexpression may also be various
among cell types. Although overexpression of Bcl6
induces cell cycle arrest at the G2/M phase and
the cooperative down-regulation of Bcl-xL and up-
regulation of Bax in CV-1 cells [23], the cell cycle
arrest does not occur in NIH3T3 cells by overexpres-
sion of Bcl6 (Fig. 2C) and overexpression of Bcl-xL
cannot rescue Bcl6(POZ3)-mediated cell death in
NIH3T3 cells (Fig. 4). Thus, the mechanism of cell
death in CV-1 (SV-40 transformed monkey kidney)
cells may be di¡erent from that in NIH3T3 (mouse
¢broblast) cells. These results suggest that the
amount of Bcl6 in each di¡erentiation step of each
type of cells is critical and inappropriate expression
of Bcl6 in improper cells induces or protects apopto-
sis by transrepressing target genes with recruiting
HDACs. This may explain mechanisms of leukemo-
genesis of B cells with the chromosomal transloca-
tion involving 3q27 [55]. Here we have identi¢ed a
new functional domain of Bcl6 that recruits HDACs,
and this domain can be a molecular target of therapy
for the leukemogenesis.
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